JOINN(SH:603127) Sou Hu Cai Jing·2025-03-31 11:29Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Zhaoyan New Drug, indicating a significant decline in revenue and profit for the year 2024 [1][2] - Zhaoyan New Drug's closing price on March 31 was 20.34 yuan, reflecting a decrease of 4.24%, with a rolling PE ratio of 205.80 times, and a total market capitalization of 15.244 billion yuan [1] - The company operates primarily in the field of non-clinical safety evaluation services for drugs, with its main products including non-clinical research services and experimental model supply [1] Group 2 - As of the 2024 annual report, 115 institutions hold shares in Zhaoyan New Drug, including 113 funds, 1 brokerage, and 1 other entity, with a total holding of 66.2129 million shares valued at 1.101 billion yuan [1] - The latest financial results for 2024 show that Zhaoyan New Drug achieved operating revenue of 2.018 billion yuan, a year-on-year decrease of 15.07%, and a net profit of 74.0754 million yuan, down 81.34% year-on-year, with a gross profit margin of 28.43% [1] - In comparison to the industry, Zhaoyan New Drug's PE ratio is significantly higher than the industry average of 51.10 times and the industry median of 44.61 times, ranking 42nd in the medical services sector [2]